SCHEMBL5364403

SCHEMBL5364403

Cc1ccc(C=C2C(=O)Nc3ccc(Br)c(C)c32)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 13/20 0.56
MEN1 O00255 12/20 0.56
POLB P06746 10/20 0.56
ALDH1A1 P00352 7/20 0.56
LMNA P02545 3/20 0.56
THRB P10828 2/20 0.56
ALOX12 P18054 2/20 0.56
DYRK1A Q13627 1/20 0.56
MAPT P10636 7/20 0.43
L3MBTL1 Q9Y468 5/20 0.43
PKM P14618 4/20 0.43
MAPK1 P28482 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
RET P07949 2/20 0.43
RECQL P46063 2/20 0.43
GFER P55789 1/20 0.43
GAA P10253 4/20 0.42
HPGD P15428 3/20 0.41
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367431 0.90 RET (0.55) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL5367226 0.85 PTPN1 (0.44) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL7138230 0.84 PTPN1 (0.43) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL5366590 0.83 MEN1 (0.55) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL5358671 0.82 RET (0.39) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL7130441 0.81 KMT2A (0.49) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL5372795 0.78 PIM1 (0.45) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL5377025 0.77 RET (0.54) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL7134014 0.77 RET (0.48) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL6854443 0.76 MEN1 (0.67) KMT2AMEN1POLBALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK KMT2A 4060/4885MEN1 3855/4885POLB 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.